Celon Pharma (FRA:8RP) Moat Score: 0/10 (As of Jul. 09, 2026)


FRA:8RP Celon Pharma SA FRA:8RP
12 GF Score
Price €4.36
GF Value €5.14
Valuation Modestly Undervalued
! 3 Warning Signs
View Full Analysis

What is Celon Pharma Moat Score?

Celon Pharma has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Celon Pharma has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Celon Pharma might have No Moat - No discernible moat.

Celon Pharma  (FRA:8RP) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Celon Pharma Moat Score Related Terms

FRA:8RP
12GF Score
Celon Pharma SA FRA:8RP
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Celon Pharma (FRA:8RP) Overvalued in 2026?

Based on GuruFocus' analysis, Celon Pharma stock appears to be undervalued. The current stock price of €4.36 is trading 15.3% below its estimated GF Value™ of €5.14. GuruFocus considers Celon Pharma to be Modestly Undervalued.

Key valuation signals for FRA:8RP:

  • Moat Score: 0
  • GF Value™: €5.14 vs. price of €4.36 (15.3% below fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the FRA:8RP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Celon Pharma Business Description

Other Exchanges CLN:Poland
Address Ogrodowa 2A, Kielpin, Lomianki, POL, 05-092
Celon Pharma SA is a Poland based company engages in the research of therapeutic solutions and development, production, distribution, and marketing of specialized generic products. It invests in the development of innovative pharmaceuticals with potential applications in the treatment of cancer, neurological diseases, diabetes and other metabolic disorders. Its products portfolio comprises pills, such as Aromek, Bosentan Celon, Donepex, Ketrel, Lazivir, and Valzek, as well as inhalation powder.
12GF Score

Get the complete analysis for FRA:8RP

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€4.36
Price
€5.14
GF Value